Mirum Pharmaceuticals

MIRM

Market cap $5.31B

MIRM completes enrollment in phase III AZURE-1 and screening in AZURE-4 for brelovitug in HDV, with top-line data expected in the second half of 2026.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus.

MIRM posts Q4 loss. Revenues jump 50% on strong Livmarli and bile acid drug sales, topping estimates in Q4 2025 and lifting shares.

Although the revenue and EPS for Mirum Pharmaceuticals (MIRM) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.02. This compares to a loss of $0.49 per share a year ago.

Mirum Pharmaceuticals, Inc. (MIRM) Q4 2025 Earnings Call Transcript

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026.

Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.